Tyra Biosciences (TYRA) Preferred Stock Liabilities (2020 - 2021)
Tyra Biosciences (TYRA) reported Preferred Stock Liabilities of $106.1 million for Q2 2021, up 107.5% quarter-over-quarter from $51.1 million in Q1 2021.
Tyra Biosciences (TYRA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Tyra Biosciences has reported Preferred Stock Liabilities for 2 years, with the latest figure at $106.1 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $106.1 million; the trailing twelve-month figure through Jun 2021 stood at $106.1 million (changed N/A YoY), and the FY2020 full-year result was $27.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $106.1 million, up from $51.1 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $106.1 million in Q2 2021, with the low at $27.7 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Tyra Biosciences | 1.67 Bn | 1.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 106.13 Mn |
| Mar 31, 2021 | 51.15 Mn |
| Dec 31, 2020 | 27.65 Mn |
| Sep 30, 2020 | 27.65 Mn |